<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01508780</url>
  </required_header>
  <id_info>
    <org_study_id>2011P000916</org_study_id>
    <nct_id>NCT01508780</nct_id>
  </id_info>
  <brief_title>Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan</brief_title>
  <official_title>Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <brief_summary>
    <textblock>
      It has been hypothesized that one of the benefits of bosentan relates to pulmonary vascular&#xD;
      remodeling. The investigators believe that this study will help document the nature of&#xD;
      beneficial changes that occur in patients with Pulmonary Arterial Hypertension (PAH) in&#xD;
      response to bosentan therapy. In turn, demonstrating that changes in pulmonary vascular&#xD;
      structure and function accompany clinical improvement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will have Optical coherence tomography (OCT) and Intravascular Ultrasound (IVUS)&#xD;
      imaging during the right heart catheterization that diagnoses them as having PAH. Subjects&#xD;
      will start their bosentan and will be followed by monthly clinic visits for 4 months. At 4&#xD;
      months they will have repeat OCT and IVUS imaging.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Due to complex study protocol, no patients have been enrolled in the study.&#xD;
  </why_stopped>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the measurement of Pulmonary arterial intimal + Medial thickening by OCT pre and post treatment with bosentan at 4 months</measure>
    <time_frame>Baseline and 4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary arterial pulsatility by IVUS pre and post treatment with bosentan at 4 months</measure>
    <time_frame>Baseline and 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary arterial pressure/elastic strain index by IVUS pre and post treatment with bosentan at 4 months</measure>
    <time_frame>Baseline and 4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Pulmonary Arterial Hypertension, bosentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects include patients being diagnosed with pulmonary arterial hypertension and starting treatment with bosentan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>St Jude Medical C7 Dragonfly Optical Coherence Tomography (OCT)</intervention_name>
    <description>All subjects will have OCT and IVUS imaging during their right heart catheterization.</description>
    <arm_group_label>Pulmonary Arterial Hypertension, bosentan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Boston Scientific Intravascular Ultrasound</intervention_name>
    <description>All subjects will have OCT and IVUS imaging during their right heart catheterization.</description>
    <arm_group_label>Pulmonary Arterial Hypertension, bosentan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. WHO GROUP 1&#xD;
&#xD;
          2. AGE 18-75&#xD;
&#xD;
          3. Baseline 6-min walk distance (6MWD) between 200 and 450 m&#xD;
&#xD;
          4. Diagnosed with pulmonary artery hypertension during right heart catheterization (Mean&#xD;
             Pulmonary Artery Pressure &gt; 25mmHg)&#xD;
&#xD;
        General Exclusion Criteria&#xD;
&#xD;
          1. Pregnant or nursing&#xD;
&#xD;
          2. Acute or chronic illness other than those associated with PAH (collagen vascular&#xD;
             disease, human immunodeficiency virus, or anorexigen use)&#xD;
&#xD;
          3. Previously received any investigational medications, prostanoids, or phosphodiesterase&#xD;
             inhibitors&#xD;
&#xD;
          4. eGFR &lt; 60&#xD;
&#xD;
          5. Angina&#xD;
&#xD;
          6. Syncope&#xD;
&#xD;
          7. Failing right ventricle&#xD;
&#xD;
          8. Hemoptysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ik-Kyung Jang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>January 3, 2012</study_first_submitted>
  <study_first_submitted_qc>January 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2012</study_first_posted>
  <last_update_submitted>February 11, 2014</last_update_submitted>
  <last_update_submitted_qc>February 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Ik-Kyung Jang, MD, PhD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

